Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

All-encompassing meeting on ALL highly rated by participants

Almost 200 delegates from over 30 countries benefitted from stimulating and excellent discussions about Acute Lymphoblastic Leukemia (ALL) at the EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia on April 12-14, 2018 in…

Read more

EHA-PTHiT Mini Hematology Tutorial

EHA and the Polish Society of Hematology and Transfusion (PTHiT) are happy to present the second virtual 'mini Tutorial'. This two-day meeting aims to assess and increase your knowledge of the treatment of myeloid and lymphoid diseases.

Read more

IVDR

As of May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect.

Read more

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more

Congratulations to the 2021 Research Grant winners!

The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.

Read more